Heparin: An old drug for new clinical applications.
Carbohydr Polym
; 295: 119818, 2022 Nov 01.
Статья
в английский
| MEDLINE | ID: covidwho-1914200
ABSTRACT
Heparin, an old but first-line anticoagulant, has been used over a century. It is a heterogeneous, linear, highly sulfated, anionic glycosaminoglycan with a broad distribution in relative molecular weight and charge density. These structural properties allow heparin to selectively interact with multiple proteins, leading to heparin's various pharmacological functions, such as anticoagulant, anti-viral, anti-tumor and anti-inflammatory activities. Clinical data suggest that unfractionated heparin or low molecule weight heparin could decrease mortality in COVID-19 patients with sepsis-induced hypercoagulation through the anticoagulant, anti-viral and anti-inflammatory activities of these drugs. Thus, the non-anticoagulant activity of heparin has again aroused attention. This review highlights recent advances in the preparation of heparin-derived drugs and clinical research on its non-anticoagulant properties over the past decade, to further the development and utilization of these important drugs.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Heparin
/
COVID-19 Drug Treatment
Тип исследования:
Прогностическое исследование
Пределы темы:
Люди
Язык:
английский
Журнал:
Carbohydr Polym
Год:
2022
Тип:
Статья
Аффилированная страна:
J.carbpol.2022.119818
Документы, близкие по теме
MEDLINE
...
LILACS
LIS